Amgen Inc. (AMGN) Down 9.6% — Should I Let It Go?
Amgen Inc. (AMGN) absorbed a punishing session on Tuesday, dropping 9.57% and surrendering $41.85 to close at $395.38 on the NASDAQ. The selloff was swift and significant, pulling shares well below recent levels and reopening a meaningful gap to the 52-week high of $447.03 reached just two weeks ago on August 25, 2026. At current prices, AMGN sits approximately 11.6% below that peak — a retreat that erases a meaningful portion of what had been a roughly 34% year-to-date run heading into the session.
Trading volume came in at approximately 2.32 million shares, running below the 90-day average of around 2.66 million. Given the magnitude of the decline, the below-average turnover suggests the move was driven more by repositioning among existing holders than by a broad wave of new sellers entering the stock.
Why Amgen Inc. Price is Moving Lower
Today's catalyst was not Amgen's own fundamentals but a clinical failure at a competitor that landed squarely on one of Amgen's most closely watched pipeline assets. On September 4, Novartis (NVS) disclosed that its Phase 3 Lp(a)HORIZON trial, enrolling 8,323 patients, failed to demonstrate a reduction in a composite measure of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization versus placebo — even though the trial drug, pelacarsen, successfully lowered Lp(a) levels in the blood. That result landed as a direct challenge to a foundational assumption underlying multiple cardiovascular programs: that mechan ically reducing Lp(a) translates into fewer adverse events. The market's reaction to that question, applied to Amgen, was immediate.
Amgen's experimental siRNA therapy olpasiran, which is currently in the Phase 3 OCEAN(a)-Outcomes study, targets the same Lp(a) pathway. That trial has now inherited the uncertainty planted by Novartis's failure, and investors were unwilling to wait for clarity before repricing the risk. It is worth noting that olpasiran and pelacarsen use different technologies and may involve meaningfully different patient populations, so the Novartis result does not prove olpasiran will fail — but it has unambiguously raised the bar for the outcome. The cardiovascular pipeline has gone from a potential catalyst to a potential liability in a single trading session.
Compounding the sentiment shift, BMO Capital downgraded AMGN from Outperform to Market Perform on September 8, pointing to the stock's roughly 34% year-to-date gain alongside loss-of-exclusivity risks as reasons to step back — even while retaining a $450 price target. The downgrade added analytical weight to what might otherwise have been a sentiment-driven overreaction, framing the risk as structural rather than temporary. It is also worth maintaining perspective on the broader business: Amgen's August 4 earnings report was genuinely strong, with adjusted EPS of $6.29 against a $5.62 consensus, revenue of $10.054 billion beating the $9.42 billion estimate, and management raising full-year 2026 revenue guidance to $38.2 billion–$39.4 billion. None of that has changed — but pipeline uncertainty has a way of overwhelming near-term earnings strength when investor confidence is shaken.
What is the Amgen Inc. Rating - Should I Sell?
Weiss Ratings assigns AMGN a B rating. Current recommendation is Buy.
That B rating rests on a foundation of genuinely strong operational metrics. Return on equity of 91.47% earns the Excellent Efficiency Index — a standout figure even for a large-cap biopharmaceutical company, reflecting how effectively Amgen's entrenched franchise drugs convert shareholder equity into earnings despite the capital intensity of drug development. Revenue growth of 9.53% and a profit margin of 22.95% together earn the Excellent Growth Index, demonstrating that the company is expanding top-line results while preserving meaningful bottom-line returns — a combination that matters in a sector where pipeline investment routinely compresses margins. The Excellent Solvency Index adds further structural support, indicating the balance sheet can absorb the kind of unexpected pipeline setback that materialized today without threatening the company's financial standing.
The Good Total Return Index suggests Amgen has historically rewarded shareholders on a total return basis, though the Fair Volatility Index is a live reminder — particularly relevant today — that the stock can move sharply when pipeline or competitive news shifts the narrative. The roughly 11.6% drawdown from the 52-week high in just a matter of sessions illustrates exactly the kind of event the Fair Volatility Index is signaling. A forward P/E of 27.16 is not egregious for a name of this quality, but it leaves limited room for error if the OCEAN(a)-Outcomes trial eventually disappoints.
Within the Health Care sector, Amgen sits alongside Eli Lilly and Company (LLY, B) and Johnson & Johnson (JNJ, B), and ahead of AbbVie Inc. (ABBV, B-), Vertex Pharmaceuticals Incorporated (VRTX, B-), and Bristol-Myers Squibb Company (BMY, B-). That relative standing reflects the underlying quality of Amgen's business — but today's session is a clear illustration that even well-rated, fundamentally sound companies carry event-driven risk that ratings alone cannot fully capture. The B rating remains intact, and the Buy recommendation stands, but investors should weigh it against the new pipeline uncertainty now embedded in the thesis.
About Amgen Inc.
Amgen Inc. (AMGN) is a Health Care company and one of the world's largest independent biotechnology companies by revenue and market capitalization. The company's commercial portfolio is built around a set of established, high-revenue franchise products across oncology, inflammation, bone health, and cardiovascular disease — including Enbrel, Prolia, Xgeva, Repatha, and Otezla — many of which generate substantial recurring revenue and sustain the company's ability to fund ongoing research and development at scale. Amgen's manufacturing capabilities, including large-molecule biologics production, represent a significant operational asset that new entrants and smaller biotechnology companies find difficult to replicate.
Beyond its marketed portfolio, Amgen has invested heavily in next-generation modalities, including small molecules, bispecific antibodies, and RNA-based therapeutics such as olpasiran — the Lp(a)-lowering siRNA therapy now under Phase 3 evaluation. The company has also expanded its pipeline footprint through acquisitions, most notably the 2023 purchase of Horizon Therapeutics, which added rare disease and inflammation assets and broadened the revenue base. Amgen's global commercial infrastructure, spanning the United States, Europe, and key international markets, gives it the reach to commercialize approvals efficiently and defend market share against biosimilar competition as certain legacy products approach patent cliffs.
Amgen's competitive advantages are rooted in decades of biologics expertise, a deep intellectual property portfolio, and long-standing relationships with payers, physicians, and health systems. The company's scale also enables meaningful investment in patient support programs and market access capabilities — functions that are increasingly important as pricing pressure across the pharmaceutical industry continues to intensify. Its diversified product mix provides a degree of resilience, though like all large biopharmaceutical companies, it remains exposed to the binary outcomes of late-stage clinical programs and the regulatory environment governing drug approval and reimbursement.
Investor Outlook
Amgen Inc. (AMGN) carries a Weiss Rating of B (Buy), and the underlying business quality that supports that rating has not changed — but the clinical landscape around its cardiovascular pipeline has become meaningfully more uncertain after Novartis's Lp(a)HORIZON failure. Investors should monitor the progress and eventual readout of Amgen's OCEAN(a)-Outcomes trial, watch for any further analyst commentary on loss-of-exclusivity risk, and mark the next expected earnings report on November 3 as a key date for updated pipeline and guidance commentary. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--